- Home
- WSHP vs ARDX Comparison
WSHP vs ARDX Comparison
Compare WSHP & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WSHP | ARDX |
|---|---|---|
| Founded | 2021 | 2007 |
| Country | British Virgin Islands | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | WSHP | ARDX |
|---|---|---|
| Price | $87.02 | $5.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $10.65 |
| AVG Volume (30 Days) | 12.9K | ★ 3.4M |
| Earning Date | 01-01-0001 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $1,110,047.00 | ★ $398,234,000.00 |
| Revenue This Year | N/A | $22.77 |
| Revenue Next Year | N/A | $28.02 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 428.16 | 58.12 |
| 52 Week Low | $20.02 | $3.21 |
| 52 Week High | $250.00 | $6.78 |
Technical Indicators
Market Signals| Indicator | WSHP | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 44.86 |
| Support Level | N/A | $5.69 |
| Resistance Level | N/A | $6.40 |
| Average True Range (ATR) | 0.00 | 0.28 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 0.00 | 3.13 |
Price Performance
Historical ComparisonAbout WSHP WeShop Holdings Limited Class A Ordinary Shares
WeShop Holdings Ltd is a community owned social commerce platform offering shoppers shares in the Company every time customers make a purchase, recommend a product or refer a new member. WeShop earns revenues from advertising on their platform and commissions on the sales through the platform.
About ARDX Ardelyx Inc.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.